Dominick DeGrazio GSK

Dominick DeGrazio joined GlaxoSmithKline in August 2022 as an Early Device Project Engineering Lead where he is responsible for de-risking drug-device combination product development of early stage assets. Most recent to GSK, Dominick was a Manager of MS&T at PTC Therapeutics and lead drug product fill-finish process development, tech transfer, and process validation activities for early and late-stage gene therapy products. Additionally, he supported the commercial launch of Upstaza, the first approved gene therapy treatment for AADC. Prior to PTC, he spent about 10 years combined between Janssen R&D, Oncobiologics, and West Pharmaceutical Services. During this time, Dominick focused on formulation, process, primary packaging and combination product device development for large molecule drug products.